A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
|Articles|February 27, 2013
Biotech Drugs Still Won't Copy
Advertisement
Much anticipated knockoff versions of costly biotech medicines are facing delays and obstacles that could cost patients and health systems billions in missed savings.
Several high-profile projects to create so-called biosimilar drugs have faltered in recent months. Merck & Co. dissolved a dedicated biosimilar unit last year and in December retreated from a plan to copy arthritis treatment Enbrel after maker Amgen Inc. gained a new patent. Last fall, Samsung Electronics Co.'s biosimilar unit suspended trials for a version of the cancer drug Rituxan, and generic-drug maker Teva Pharmaceutical Industries Ltd. halted its own Rituxan push.
Read the full story:
Source: The Wall Street Journal
Advertisement
Related to this article
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
A meta-analysis found teleophthalmology satisfaction comparable to in-person eye care, but showed a gap between recommending it and reusing it.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Advertisement
Advertisement
Trending on AJMC
1
Up to 400 mg of Caffeine Daily Is Safe for Most Adults, AHA Says
2
Postvaccine Hepatitis Reports More Often Serious in Children vs Adults
3
Perspectives on Health-Related Social Needs for Medicare Advantage Beneficiaries
4
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
5